Using colocalization analysis, polygenic risk scores, and Mendelian randomization approaches, we identified a causal association of LPC O-16:0 with T2D, represented by a lead variant in CD45, a key regulator of T- and B-cell antigen receptor signaling, and is already used as a therapeutic target. This evidence concerns the gene PTPRC and type 2 diabetes mellitus.